Retailers like Walmart and Costco gain market share through direct-to-consumer GLP-1 prescription programs
As employers reduce coverage of GLP-1 weight-loss drugs, more Americans are turning to direct-to-consumer (DTC) prescription programs. Retail giants such as Walmart, Costco, CVS, and Amazon are capitalizing on this shift by offering these prescriptions at competitive prices—some starting as low as $25 a month—to attract customers and build long-term relationships. These DTC initiatives serve not only to sell the drugs but also act as customer acquisition tools. Retailers aim to leverage GLP-1 prescriptions as an entry point into broader consumer interactions, encouraging patients to fill other prescriptions and make additional purchases in-store or online. Experts suggest that this recurring prescription model offers a reliable revenue stream for retailers. The strategy is part of a larger effort by retail pharmacy chains to benefit from the weight-loss drug boom despite low profit margins on medications themselves. By offering GLP-1 drugs at discounted rates, these companies are also promoting their loyalty programs and memberships—such as Costco’s $65 membership—which could further enhance customer retention.
Tickers: $AMZN $COST $CVS $LLY $NVO $WMT
Topics: direct-to-consumer prescriptions GLP-1 drugs retail pharmacy competition